Objectives: To investigate the diagnostic and prognostic value of HMGB1 when used as a urinary biomarker in patients with renal cell carcinoma.
Methods: The study was conducted in a total of 99 participants including 34 patients diagnosed with Renal cell carcinoma [RCC], 34 patients with an acute urinary tract infection [UTI] and 31 healthy controls.Urinary HMGB1 levels of the study groups were evaluated. Urinary HMGB1 levels and tumor diameter among patients with different subtypes of renal cell carcinoma were comparison.
Results: Urinary HMGB1 levels differed significantly among the three groups [p<0.001]. Pairwise comparisons revealed statistically significant differences between RCC and UTI groups [p<0.001] and between RCC and control groups [p<0.001]. No significant difference was detected between acute UT In and control groups [ p=0.078]. Urinary HMGB1 levels were significantly different when compared among RCC subgroups, [ p=0.035], with a much higher median value [499,9 pg/mL] in the sarcomatoid type in particular. The tumor diameter also significantly differed among patients with different types of RCC [p=0.002]. Specifically, a much greater tumor diameter was found in patients with the sarcomatoid type. The cut-off values derived from the ROC analysis were 104.85 pg/mL for distinguishing RCC from a UTI, 35.15 pg/mL for acute UTI versus controls, and 87.55 pg/mL for RCC versus. Sensitivity 79%, specificity was found 85%. Conclusion: Urinary HMGB1 levels as measured by a non-invasive method in the present study were higher in renal cell carcinoma and closely associated with high-grade tumor.